INTRODUCTION
Primary cutaneous T-cell lymphomas comprise heterogeneous entities with diverse histological, phenotypic and molecular genetic features dependent on the respective cell of origin [1] .
Most T-cell lymphomas of the skin exhibit a skin-homing CD4? T-helper cell phenotype.
CD8? cutaneous lymphomas usually represent rare CD8? variants of otherwise common and well-characterized CD4? lymphomas, such as CD8? variants of mycosis fungoides (MF) and Sézary syndrome (SS), CD30?
lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) or peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) [2] . In contrast, an exclusive CD8? phenotype is present in the eponymous CD8? acral T-cell lymphoma [3] formally known as CD8? indolent lymphoid proliferation (ILP) [4] as well as in aggressive epidermotropic cutaneous T-cell lymphoma (AECTCL) [5] . Tables 2 and 3 , respectively. Survival data are shown in Fig. 1a .
With respect to CD8? MF, atypical clinical features mimicking cutaneous mastocytosis or purpura pigmentosa (Fig. 2a ) and pityriasis alba (Fig. 2b) commonly diverted the clinician from a prompt initial diagnosis. The corresponding histological pattern was otherwise rather similar to classical CD4? MF (Fig. 2c,d lymphoma infiltrates, but was also true for all studied cases of CD8? lymphomas: overall survival was 74 ± 63 months for patients with localized disease manifestation as compared to 31 ± 30 months for patients exhibiting multiple lesions (P = 0.01).
In addition to clinical features, we were also interested in thorough histological and immunohistological characterization of our selected CD8? lymphomas. Histological features and further immunophenotypic characterization are depicted in Tables 2 and 3 .
Whereas most of the MF cases showed smalland medium-sized neoplastic cells with rare large-cell transformation and systemic PTCL-NOS showed large neoplastic cells, cell size was otherwise rather evenly distributed among the different entities (Fig. 3b, d) . were not associated with a more aggressive subtype or a worse clinical course. To note, PIM1 expression was observed with a moderate AECTCL aggressive epidermotropic primary cutaneous T-cell lymphoma, ILP acral CD8? T-cell lymphoma, formerly indolent CD8? lymphoid proliferation, PTCL peripheral T-cell lymphoma, SD standard deviation, SPTCL subcutaneous panniculitis-like T-cell lymphoma While in our analysis most of the cases of MF presented with small lymphoma cells, large tumor cells with partly blast-like morphology were prevailing in both primary cutaneous and secondary cutaneous PTCL-NOS. With respect to MF, large-cell transformation has been established as an independent negative prognostic factor, irrespective of age, tumor stage and IPI score and independent of concomitant CD30 expression [10] . In one of the largest recent studies addressing the predictive impact of cytology in 82 patients with cutaneous cytotoxic PTCL-NOS, small-/ medium-sized cell type turned out to have prognostic impact [11] . However, divergent from our approach, both CD4? and CD8?
PTCL-NOS presenting with a cytotoxic phenotype were included in this analysis, and the favorable subgroup of small-/medium-sized lymphomas was mainly attributed to CD4? small-/medium-sized pleomorphic T-cell Extent of skin lesions is one of the major categories within the IPI for predicting the biological behavior of systemic PTCL and accordingly directing further therapeutic approaches [11] . Solitary skin lesions were attributed to a longer overall survival in our 35
cases of CD8? cytotoxic lymphomas.
A recent study highlighted the negative prognostic impact of both c/ë-T-cell receptor expression (Vë1 subset) and deep subcutaneous involvement in cutaneous T-cell lymphoma [11] . However, rare expression of c/ë-T-cell receptor chains may also be observed in CD4? or CD8? cutaneous lymphomas, such as MF, anaplastic large-cell lymphoma or pagetoid reticulosis, and these lymphomas run a rather [13] . In less than 1% of cases, lineage infidelity with, e.g., aberrant expression of CD20 or concomitant dual expression of both c/ë-chains and ab-chains of the T-cell receptor [14] may be observed, as was present in one case of cutaneous PTCL-NOS in our study.
With regard to T-cell antigen expression, it has been initially postulated that loss of several T-cell markers, such as CD2 and CD5, could serve as a diagnostic clue for AECTCL and thus portend a worse prognosis [6, 7] . However, more recent studies, including ours, showed more variable and inconsistent expression (or loss) of the T-cell antigens CD2, CD5 and CD7 [15] , so these immunophenotypic features do not serve as helpful diagnostic adjuncts. [19, 21, 22] . Gene expression profiling has once again confirmed that within the generic term of systemic PTCL-NOS, there is extensive molecular heterogeneity as already evidenced by divergent clinical, histological and immunophenotypical data [18, 23, 24] . Moreover, taking the limited therapeutic opportunities and the often dismal prognosis of PTCL-NOS into consideration, the progress in deciphering the mutational landscape and the subtype-specific gene expression profiles has revealed several novel therapeutic options [25] .
Putative targets include the network of epigenetic modifiers [26] as well as the NFjB, STAT and JAK pathways [27] , PIM kinases [27] and downstream signaling of tyrosine receptors, such as PDGFRa [28] and VEGFR [29] . In the lymphoma cases presented here, the expression pattern of PIM1 (which was actually present in almost all cases), VEGFR or PDGFRa (which were almost altogether absent in our cohort) did not serve as putative prognostic markers, so that these data could not be recapitulated in our CD8? cutaneous lymphoma cohort.
CONCLUSIONS
Our retrospective analysis once again underlines that when dealing with CD8? cutaneous lymphoma, the crucial approach still remains to unify the histological and clinical data to make a correct diagnosis with prognostically relevant subtype attribution as long as better immunophenotypical and especially genetic data are still lacking. In the future, molecular profiling of such rare lymphoma variants will hopefully contribute to ameliorate treatment strategies as a result of more precise subtype definition and to develop more individualized treatment strategies, including targeted therapies. As cutaneous CD8? lymphomas represent rare entities and our study data are therefore limited in its conclusions, a broader multi-institutional approach for these lymphoma entities is urgently warranted in the future.
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